MedPath

Diaphragmatic Ultrasound in Acute Hypoxic - Hypercapnic Respiratory Failure (ARF)

Not Applicable
Completed
Conditions
Acute Hypoxic - Hypercapnic Respiratory Failure (ARF)
Interventions
Diagnostic Test: D-US ARF
Registration Number
NCT03314883
Lead Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
Brief Summary

Mortality of acute hypoxic - hypercapnic respiratory failure (ARF) patients underwent invasive mechanical ventilation is demonstrated to be higher than in patients who underwent only non invasive mechanical ventilation (NIV).

There is an increased need to detect more predictive factors for NIV failure, in order to better identify patients most at risk of facing negative outcomes.

The aim of this experimental pilot study is to evaluate the feasibility of the ultrasound of diaphragm in ARF patients underwent non invasive mechanical ventilation ( primary endpoint ).

Furthermore the secondary aim is to observe any relationship between diaphragmatic function (excursion), diaphragmatic thickening and the timing of arterial blood gases (ABGs) compensation in patients with ARF undergoing NIV treatment; additional outcomes are: correlation with dyspnea level, time of mechanical ventilation, NIV failure, rate of tracheostomy, length of stay in ICU and in-hospital and 90-day mortality.

Detailed Description

Inclusion criteria: respiratory failure resulting in respiratory acidosis to be treated with NIV, age\> = 18 years

Exclusion criteria: acute pulmonary edema, coexisting interstitial pathologies, neuromuscular pathologies, thoracic cage's deformity, previous diaphragmatic paralysis, hemodynamic instability, intracranial hypertension, pregnancy, absolute contraindications to NIV, need for immediate intubation, recent thoracotomy, presence of pneumothorax or pneumomediastinum.

After patient's triage, transfer to Shock Room and primary assessment by emergency department staff ,diaphragmatic ultrasound is performed when NIV indication is given.

NIV is delivered with a facial mask; ventilation is set in NIV application, pressure support mode. Positive end expiratory pressure (PEEP) and Inspired oxygen fraction (FiO2) are adjusted to obtain a peripheral oxygen saturation (Spo2) between 88-92%. The pressure support is set to achieve a target volume of between 6-8 (ml / kg) and a respiratory rate \< 30 respiratory acts per minute.

Respectively one and two hours after starting NIV, diaphragmatic ultrasonography and ABGs analysis are again performed.

NIV failure criteria are defined by the need for endotracheal intubation or by death.

Criteria for NIV failure: unchanging or worsening blood gases despite NIV; need to protect airways due to neurological deterioration or massive secretions; haemodynamic instability or major electrocardiographic abnormalities; uncontrolled dyspnea and NIV intolerance/ refusal.

General measures On admission clinical severity is recorded by Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation II Score (APACHE II).

ABGs values ( PH, arterial oxygen tension (paO2), arterial carbon dioxide tension (paCo2), paO2/FiO2, bicarbonates (HCO3), lactate) will be recorded before NIV, at 1 hour and 2 hours later.

Chest X-ray and peripheral blood sample (hemochrome with band cell count, C-reactive protein (CRP) and electrolytes) will be performed within 24 hours of admission.

The presence of pneumonia, sepsis and previous treatment with systemic or inhaled steroids will be recorded.

Diaphragm Ultrasound

Ultrasound evaluation of diaphragm function is performed on admission before starting NIV, 1 hour and 2 hours later.

Diaphragmatic function is assessed by a B-Mode ultrasound device connected to a linear probe ( 7-12 MHz) at the patient's bedside.

Measurements are performed on a patient in supine position with a recessed back angle between 20 and 40 degrees.

Probe position is set between 8th and 10th intercostal space on the mid axillary line to find the apposition zone of the diaphragm, where lung, diaphragm and abdominal parenchyma are identifiable.

Diaphragmatic thickness is measured at end-inspiration ( Ti) and end- expiration (Te).

The percentage change in diaphragmatic thickness (ΔTdi) is calculated as follows:

ΔTdi % = (Ti- Te) / Te \* 100 Measurements are performed three times and the average value of the three measurements is considered.

Diaphragmatic excursion is also evaluated.

Statistical analysis As it is an experimental pilot feasibility study, 20 patients will be initially enrolled.

Descriptive statistics for continuous variables will be presented as median and interquartile. Non-parametric continuous variables will be evaluated by non-parametric Wilcoxon test (Mann-Whitney).

Categorical variables will be evaluated by chi-square or Fisher's test.

The influence of diaphragmatic thickening and muscle thickness on NIV failure, mortality and hospitalization's days wil be assessed through correlation analysis A P-value \<0.05 will be considered significant.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • respiratory failure resulting in respiratory acidosis to be treated with NIV
  • Age> = 18 years
Exclusion Criteria
  • acute pulmonary edema
  • coexisting interstitial pathologies
  • neuromuscular pathologies
  • thoracic cage's deformity
  • previous diaphragmatic paralysis
  • hemodynamic instability
  • intracranial hypertension
  • pregnancy
  • absolute contraindications to NIV
  • need for immediate intubation,
  • recent thoracotomy
  • presence of pneumothorax or pneumomediastinum

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
D-US ARFD-US ARFDiaphragmatic evaluation, i.e thickening fraction (%) and excursion (millimeters), will be performed 3 times in the first two hours after acute hypoxic - hypercapnic respiratory failure (ARF) patients admission
Primary Outcome Measures
NameTimeMethod
Feasibility of diaphragm ultrasound function evaluation (excursion and thickening) in acute hypoxic - hypercapnic respiratory failure (ARF) during the first two hours after emergency department admission.2 hours

Ultrasound will be performed before starting NIV, after 1 and 2 two hours of NIV application

Secondary Outcome Measures
NameTimeMethod
dyspnea level at 1 hour1 hour

dyspnea level evaluated via visual analogical scale

Monitoring diaphragmatic function in terms of excursion at 1 hour1 hour

Diaphragmatic excursion (millimeters) computed as diaphragmatic displacement during breath

Arterial blood carbon dioxide (PaCO2) compensation evaluation2 hours

PaCO2 after two hours from NIV application

Monitoring diaphragmatic function in terms of thickening at 2 hours2 hours

Diaphragmatic thickening (%) \[(inspiratory thickness - expiratory thickness)\]/expiratory thickness \* 100

Days spent in intensive care unit28 days

Amount of days spent in ICU

dyspnea level at 0 hour0 hour

dyspnea level evaluated via visual analogical scale

Monitoring diaphragmatic function in terms of thickening at 1 hour1 hour

Diaphragmatic thickening (%) \[(inspiratory thickness - expiratory thickness)\]/expiratory thickness \* 100

Monitoring diaphragmatic function in terms of excursion at 0 hour0 hour

Diaphragmatic excursion (millimeters) computed as diaphragmatic displacement during breath

Monitoring diaphragmatic function in terms of excursion at 2 hours2 hours

Diaphragmatic excursion (millimeters) computed as diaphragmatic displacement during breath

dyspnea level at 2 hours2 hours

dyspnea level evaluated via visual analogical scale

Monitoring diaphragmatic function in terms of thickening at 0 hour0 hour

Diaphragmatic thickening (%) \[(inspiratory thickness - expiratory thickness)\]/expiratory thickness \* 100

Days spent in in hospital90 days

Amount of days spent in hospital

Trial Locations

Locations (1)

A.O.U Maggiore della Carità

🇮🇹

Novara, Italy

© Copyright 2025. All Rights Reserved by MedPath